Canadian Rt Pcr Test Kits Suppliers and Manufacturers

Veterinary diagnostic tests, ELISA, PCR, rapid kit test.Manufacturer & exporter

-:-Nitrile-gloves -:-Masks -:-Gowns -:-RT-PCR Test Kits -:-IgG/IgM Antibody Rapid Test Kits -:-Any PPE requirements please ask.

Ppe, masks, gloves, face shields, ppe closeout, pcr kits, covid test kit, rapid antigen tests.

A box 2 doses I HEALTH price $6+10% A Box 1 dose Flow Flex Price $4.4 +10% You can be seller mandate DDP USA AND ALL OVER WORLD ATTENTION PAYMENT SBLC or BCL /PB Moq 500K MAX 5-10MX12Month DDP USA or World BY AIR Buyer side 50% Commission open You can be seller part 10% of 50% for you SOP: 1, Documents NCNDA ICPO KYC 2 Seller FCO 3 DRAFT SPA DRFT SBLC OR BCL /PB 4 SPA sign &IMFPA 5 ATTENTION PAYMENT SBLC/BCL /PB / TT 6,Can get Allocation letter after confirm payment 7 DDP buyer Port Inspection pay TT 8 Then keep rolling for next deal Notice 1,You can Mark up 2 you can be seller part 3 DDP to your warehouse 2022 Feb 26-Mar 10

Medical Supplies, Nitrile Medical Premium Gloves, Antigen Covid 19 Quick Tests, All Other Related Products.

Euro pallets, lithium ore (full solution), medical ppe products of nordic protect brand, a4 paper, covid test kits, wood pellets, coal, halal chicken, halal beef.

Health and beauty and protective prod ppe (personnel protective equipment in stock), control & calibrator, dental merchandise, diagnostic instruments, equipment & furniture, extended care home health, gloves, infection control, instruments, iv products, lab point of care, lab equipment & accessories, medical supplies, needles & syringes, injection devices, miscellaneous products, injection products, needle removal disposal, needles, biopsy, dental safety, specialty spinal standard, syringe needle combo's, insulin safety, insulin standard, syringe needle combo safety, syringe needle combo standard, tuberculin safety, tuberculin standard, syringes, dental insulin, irrigation, miscellaneous safety specialty standard, tuberculin, orthopedic & physical therapy, patient care & exam room supplies, otc, protective apparel, radiology, respiratory & oxygen, safety and emergency, ethicons and covidiens,.

Rapid Test Kit COVID-19 IgG/Igm. Standard certification. FDA CE 38220090.00 ( Including in the WHO listing) MQO 10,000 units

We at Phoenix Bioscience would like to offer you our COVID-19 rapid detection kit based on detecting SARS-COV-2 IgG and IgM and delivers results within 15 minutes. Made in Canada, CE certified. Packaging Details: Each package contains 25 individually packed tests, the buffer used in the detection procedure, and disposable pipettes for blood samples collection Phoenix Bioscience is offering a competitive price for a high-quality kit

2.8million Covid-19 Rapid Test Kits In Stock

COVID 19 Rapid Test Kit - Approved already in several asian countries. Made in FDA approved facility. MOQ: 10,000

Our COVID-19 rapid test kit can be used effectively on many levels for proper screening and strategic preparedness toward the pandemic. The test kit requires no sophisticated equipment nor laboratory settings. Our SARS-COV-2 Antibody Rapid Test Kit can be applied for screening of COVID-19 disease on the following: General practitioners and external clinics level to detect previous SARS-COV-2 viral infections on both symptomatic and asymptomatic patients. Determination of the immunity level of front-line healthcare workers, which can help in the development of pandemic preparedness strategies at national levels. Epidemiological COVID-19 surveys at national and district levels for research purposes. Airport screening for arriving /departing passengers to control the pandemic in the aviation industry. Suspected cases exclusion to minimize cost and time spent in the RT-PCR testing procedures. Screening on the national level to facilitate decision making regarding lockdown and curfew easing strategies. Phoenix Bioscience is offering a competitive price for a high-quality kit that is made in Canada and used currently to combat the pandemic in most American cities.

Health Canada Authorised Rapid Test The COVID-19 antigen rapid test device is a lateral flow in-vitro immunoassay intended to be used for the qualitative detection of the SARS-CoV-2 viral nucleoprotein. This device will detect both viable and nonviable virus in both nasopharyngeal and oropharyngeal secretions. This test had been authorized for point of care use by Health Canada and is available for immediate dispatch MediGuard Systems of Canada is an Authorised distributor of the Assuretech Rapid Antigen test. Support documentation and details available on request

Assay+ COVID-19 antigen rapid test is authorized with CE marker, the sensitivity is 90%, the specificity is 98.5%. Assay+ Covid 19 antigen rapid test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 from the nasopharyngeal swab from the suspected COVID-19 patients within five days of symptom onset. This test is an aid to differentiate Covid 19 virus infection from other respiratory tract infection caused by coronavirus 229E, NL63, OC43 and HKU1, or severe acute respiratory syndrome caused by SARS-CoV and MERS-CoV. The test should be performed in moderate, high or waived complexity tests. This test can also perform for the Point of Care (POC) purpose.

The COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test Device utilizes lateral flow technology that is used for the qualitative, differential detection of both anti-SARS-CoV-2 IgM and IgG antibodies. In general, antibodies can be detected 1-3 weeks after infection. This test is intended to screen patients for COVID-19. Combining RNA and Antibody tests can significantly raise the sensitivity for detecting COVID-19 in infected individuals. This test has been authorized by the FDA under a EUA for professional use CLIA and CLIA WAIVED for Point Of Care. This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. This product is intended for professional use and not for home use. FACT SHEET FOR HEALTHCARE PROVIDERS This test has been authorized by the FDA under a EUA for use by authorized CLIA laboratories. This device is CLIA waived for point of care use for fingerstick whole blood specimens only. The user should be trained in the procedure. Wear appropriate protective attire for your safety when handling patient samples. This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. There should be a blue line in the control region (next to ) before testing, discard the device if there is no blue line.

Boson rapid antigen tests kits boxes of 20

Made in Canada Health Canada approved CE Mark and ISO certified The product has proven to have 100% Specificity and 96% Sensitivety Stock availabity: 2 Million tests/kit in Canada Production: up to 5 Million tests/kit weekly The Rapid Response COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset. This test is authorized for use at the Point of Care i.e., in patient care setting. Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigen is generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patientâ??s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The Rapid Responseâ?¢ COVID-19 Antigen Rapid Test Device is for use at the Point of Care for professional use only. PRODUCT INFORMATION: Product: Rapid Respose Sample: Nasal / Nasopharyngeal secretions Format: Cassette Quantity: 25 Tests/Kit per box Time to result: 15 minutes Storage Condition: 2-30 C/36-86 F Test Principle: Immunochromatographic Assay CONTENTS - Individually packed test devices Extraction Buffer Extraction tube Nozzle with filter Tube stand Individually packed swabs Package Insert

Highest accuracy Fast result interpretation Cost effective Made with best choices of materials Type: immunoassay system Brand name: ntbio/oem/private label Place of origin: british columbia, canada Size: 60mm x 300mm Accuracy: 99.9% Sensitivity: 20 miu/ml Specimen: urine .